Opportunities for collaboration

GLYCART is looking to in-license antibodies where the improvement of target cell killing will likely have a clinical benefit (for indications in oncology and autoimmune diseases).


The Roche Group has a number of antibody-drug candidates that can benefit from the GlycoMAb technology and this will be the immediate focus for the Roche-GLYCART team. To the extent there is excess capacity, Roche will review the possibility of collaborations using the GlycoMAb technology, particularly with existing Roche partners.